Specific anchoring of Survivin in the nucleus of glioma cells, e.g., using specific molecules binding the Survivin’s NES to prevent interaction with its related CRM1 receptor, or administration of small-molecule inhibitors, specifically interfering with cytoplasmic Survivin, would ameliorate TMZ response. This evidence concerns the gene BIRC5 and central nervous system cancer.